Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Yahoo Finance reports.
Matinas BioPharma Trading Down 6.1 %
Shares of MTNB stock opened at $0.27 on Friday. Matinas BioPharma has a 52-week low of $0.11 and a 52-week high of $0.89.
Hedge Funds Weigh In On Matinas BioPharma
Several large investors have recently made changes to their positions in the company. Private Advisor Group LLC raised its position in Matinas BioPharma by 59.7% during the first quarter. Private Advisor Group LLC now owns 239,494 shares of the company’s stock worth $192,000 after acquiring an additional 89,553 shares during the period. BlackRock Inc. raised its position in shares of Matinas BioPharma by 0.7% during the 1st quarter. BlackRock Inc. now owns 4,325,053 shares of the company’s stock worth $3,479,000 after purchasing an additional 29,643 shares during the last quarter. Atria Wealth Solutions Inc. purchased a new position in Matinas BioPharma in the 1st quarter valued at about $32,000. State Street Corp increased its stake in Matinas BioPharma by 8.0% during the 1st quarter. State Street Corp now owns 712,471 shares of the company’s stock worth $573,000 after buying an additional 52,897 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Matinas BioPharma during the second quarter valued at approximately $73,000. 11.77% of the stock is currently owned by institutional investors and hedge funds.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
See Also
- Five stocks we like better than Matinas BioPharma
- Insider Trades May Not Tell You What You Think
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How is Compound Interest Calculated?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is the FTSE 100 index?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
